Buprenorphine Extends Ketamine Anti-Suicidal Effects in New Study

A Stanford Medicine clinical trial has found that low-dose buprenorphine, a cornerstone of medication-assisted treatment for opioid use disorder, may also dramatically extend the anti-suicidal effects of ketamine infusions in patients with major depressive disorder.

It offers a potential new lifeline for one of psychiatry’s most vulnerable and undertreated populations. The study, published May 18, 2026, in the American Journal of Psychiatry, is the first pharmacological method shown to prolong ketamine’s temporary relief from suicidal ideation.

Why Medical Detox and MAT Research Matter Beyond Addiction

Buprenorphine is already well established in medication-assisted treatment programs as a partial opioid agonist used to manage opioid dependence and ease withdrawal.

In that context, it works by binding to opioid receptors in the brain without producing the intense euphoria of full opioids, reducing cravings and supporting medically supervised detox.

This new research suggests the drug’s action on the brain’s opioid system may also serve a role far outside traditional addiction medicine.

Stanford researchers theorized that because ketamine’s antidepressant effects are partially mediated through opioid receptors, not just its well-known glutamate-blocking mechanism, a low-dose opioid-active agent like buprenorphine might help sustain those effects. Their hypothesis proved correct.

What the Study Found

The clinical trial enrolled 45 patients with major depressive disorder and suicidal ideation. All received a single ketamine infusion; 48 hours later, they began a four-week daily regimen of either low-dose buprenorphine or a placebo.

The buprenorphine dose was intentionally modest, starting at 0.2 mg per day in the first week and increasing to 0.8 mg per day by the fourth week, roughly 5–10% of the dosage used for pain management or opioid replacement therapy.

The results were striking. After one month, 78% of patients in the buprenorphine group remained responsive to treatment, meaning their suicidal ideation scores had fallen to less than half their starting levels, compared to just 48% of patients who received the placebo.

On a 38-point scale for suicidal ideation, patients in the buprenorphine group scored an average of 3.6 at the one-month mark, well below the threshold of 6 considered clinically significant. Those in the placebo group averaged 8.7, hovering just above that threshold.

Notably, the use of buprenorphine did not appear to significantly extend ketamine’s antidepressant effects, only its anti-suicidal effects.

Researchers believe this divergence points to distinct underlying biological mechanisms, an important distinction that could eventually shape more targeted treatment protocols.

Understanding Buprenorphine in Medical Treatment

Buprenorphine (also marketed as Suboxone when combined with naloxone) is one of the three FDA-approved medications used in medication-assisted treatment for opioid use disorder, alongside methadone and naltrexone.

In medically supervised detox and long-term MAT programs, it reduces opioid withdrawal symptoms, prevents relapse, and stabilizes patients biologically so they can engage in therapy and recovery.

In this study, the drug was used at a fraction of the standard MAT dose, suggesting that its opioid-receptor activity, even at low levels, may have therapeutic value beyond addiction medicine, particularly in modulating how the brain processes mood and suicidality.

What This Means for Patients in Detox and Recovery

The connection between suicidality and substance use disorders is well documented. People undergoing detox, particularly from opioids, face elevated psychiatric risk, including depression and suicidal ideation, especially in the weeks immediately following cessation of use.

This research raises an important clinical question: could the ketamine-plus-buprenorphine sequence eventually be used to address co-occurring suicidality in patients already engaged in medication-assisted treatment or opioid detox programs?

While the study was not designed to answer that question directly, the findings underscore how buprenorphine’s mechanisms extend well beyond managing physical withdrawal.

Senior author Dr. Alan Schatzberg noted that the extended window of relief could give patients enough time to try other therapies, such as conventional antidepressants that can take several weeks to take effect, or to connect with the right therapist or support resources.

Currently, there are no FDA-approved drugs specifically indicated for suicidal ideation in major depressive disorder, in part due to a lack of studies targeting this population, who are frequently excluded from clinical trials for safety reasons. This study is a meaningful step toward closing that gap.

Finding Medical Detox and MAT Programs

If you or someone you love is struggling with opioid dependence, alcohol use disorder, or co-occurring mental health conditions, medically supervised detox is the safest and most effective starting point.

Never attempt alcohol or benzodiazepine detox without medical supervision. Withdrawal from these substances can trigger life-threatening seizures, cardiovascular complications and severe psychiatric crises, including suicidal ideation, without proper clinical management.

Medication-assisted treatment programs, including those utilizing buprenorphine, methadone or naltrexone, are available at medical detox centers nationwide. Search detox.com’s directory to find detox treatment options near you or call 800-996-6135(Sponsored) speak with a treatment advisor today.